Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 760 • 2012 ACR/ARHP Annual Meeting
Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase 3 Clinical Trial
Fabrizio De Benedetti¹, Nicolino Ruperto², Graciela Espada³, Valeria Gerloni⁴, Berit Flato⁵, Gerd Horneff⁶, Barry L. Myones⁷, Karen Onel⁸, James Frane⁹, Andrew Kenwright¹⁰, Terri H. Lipman¹¹, Kamal N. Bharucha⁹, Alberto Martini⁷ and D. J. Lovell¹², ¹Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, ³Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ⁴Istituto Gaetano Pini, Milan, Italy, ⁵Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁶Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ⁷Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁸PRCSG, Cincinnati, OH, ⁹Genentech, South San Francisco, CA, ¹⁰Roche, Welwyn Garden City, United Kingdom, ¹¹University of Pennsylvania School of Nursing, Philadelphia, PA, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA), characterized by chronic arthritis associated with prominent systemic and laboratory features, also has a significant impact on the growing…
Abstract Number: 2011 • 2012 ACR/ARHP Annual Meeting
ACR Criteria, Providers’ Global Rating of Change and Role of Patient Self-Report in Evaluating Change in Disease Over Time: A Patient Reported Outcomes Measurement Information System Study
Bin Huang¹, Jennifer Farrell², Adam Carle³, Stacey Niehaus³, Hermine Brunner⁴, Alexei A. Grom⁵, Michael Henrickson⁶, Jennifer L. Huggins⁴, D. J. Lovell⁷, Tracy V. Ting⁴ and Esi M. Morgan DeWitt², ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati, OH, ⁶MLC 4010, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: As part of a longitudinal study of Juvenile Idiopathic Arthritis (JIA), providers completed clinical outcomes assessments and patients (pt) completed self-report measures at clinic…
Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting
Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Yukiko Kimura¹, Jennifer E. Weiss², Kathryn L. Haroldson¹, Tzielan C. Lee³, Marilynn G. Punaro⁴, Sheila K. Feitosa de Oliveira⁵, C. Egla Rabinovich⁶, Meredith P. Riebschleger⁷, Jordi Anton⁸, Peter R. Blier⁹, Valeria Gerloni¹⁰, Melissa M. Hazen¹¹, Elizabeth Kessler¹², Karen Onel¹³, Murray H. Passo¹⁴, Robert M. Rennebohm¹⁵, Carol A. Wallace¹⁶, Patricia Woo¹⁷, Nico M. Wulffraat¹⁸ and CARRAnet Investigators¹⁹, ¹Pediatric Rheumatology, JM Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Pediatrics, Baystate Children's Hospital, Springfield, MA, ¹⁰Pediatric Rheumatology, Gaetano Pini Chair of Rheum, Milan, Italy, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁴Pediatrics, Medical University of South Carolina, Charleston, SC, ¹⁵Pediatric Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ¹⁶Pediatrics, Seattle Childrens Hospital, Seattle, WA, ¹⁷Division of Infection and Immunity, University College London, London, United Kingdom, ¹⁸Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Durham
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective. Pulmonary artery…
Abstract Number: 2018 • 2012 ACR/ARHP Annual Meeting
Juvenile Idiopathic Arthritis in Adulthood: Evaluation of Disease Activity, Damage and Quality of Life
Alessandra Salmaso¹, Lorenzo Ceri², Serena Capannini², Francesco La Torre³, Maurizio Gattinara⁴, Irene Pontikaki¹, Pier Luigi Meroni⁵, Fernanda Falcini² and Valeria Gerloni¹, ¹Pediatric Rheumatology, G. Pini Institute, Department and Chair of Rheumatology, Milan, Italy, ²Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Firenze, Italy, ³DIMIMP-University, Rheumatologic Section, Bari, Italy, ⁴Pediatric Rheumatology, Pediatric Rheumatology, G. Pini Institute, Department and Chair of Rheumatology, Milan, Italy, ⁵Dept. of clinical and community science, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: : Health outcomes in Juvenile Idiopathic Arthritis (JIA) have been a very active area of research in the past several years. Altogether, the available…
Abstract Number: 475 • 2012 ACR/ARHP Annual Meeting
Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
Ankur A. Kamdar¹, Patricia C. Giclas² and Barry L. Myones³, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Pediatric Allergy and Immunology, National Jewish Health, Denver, CO, ³Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: There is a paucity of data regarding response to vaccinations in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). It is also…
Abstract Number: 2019 • 2012 ACR/ARHP Annual Meeting
A Novel MRI Scoring System for the Evaluation of Early-Stage Disease Activity of the Wrist in Juvenile Idiopathic Arthritis
Charlotte M. Nusman¹, Robert Hemke¹, Taco W. Kuijpers², Eline E. Deurloo¹, Dieneke Schonenberg³, J. Merlijn Van den Berg⁴, Koert M. Dolman⁵, Marion A.J. Van Rossum⁴ and Mario Maas¹, ¹Department of Radiology, Academic Medical Center, Amsterdam, Netherlands, ²Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ³Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, ⁵Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands
Background/Purpose: Evidence that early therapeutic intervention prevents structural damage in juvenile idiopathic arthritis (JIA) patients requires focus on early-stage disease activity scores. Most outcome measures…
Abstract Number: 339 • 2012 ACR/ARHP Annual Meeting
Differences Between Juvenile and Adult Rodents with Collagen Induced Arthritis
Tracy D. Wilson-Gerwing¹, Isaac V. Pratt², David M.L. Cooper², Tawni I. Silver³ and Alan M. Rosenberg⁴, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Anatomy and Cell Biology, University of Saskatchewan, Saskatoon, SK, Canada, ³Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is among the most common chronic diseases of childhood. Arthritis is a potentially disabling disease that can result in ongoing…
Abstract Number: 1837 • 2012 ACR/ARHP Annual Meeting
Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
Alain Saraux¹, Jacques Benichou², Chantal Deslandre³, Loic Guillevin⁴, Latifa Idbrik⁵, Jean Sibilia⁶, Marc Soudan⁵, Daniel Wendling⁷ and Francis Guillemin⁸, ¹Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France, ²INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, EA4438 Laboratoire Physiopathologie des Arthrites, Rouen, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ⁵Ecole de Sante Publique, Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, France, ⁶Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ⁷Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁸Hopitaux de Brabois, Nancy, France
Background/Purpose: Comprehensive guidelines for anti-TNFα were proposed in 2005 by the French Society for Rheumatology (SFR) in France; they did not include any economic considerations…
Abstract Number: 317 • 2012 ACR/ARHP Annual Meeting
Fatty Acid Profiling: Potential New Biomarkers in Juvenile Idiopathic Arthritis (pilot study)
Weng Tarng Cham¹, Enzo Ranieri², Janice Fletcher² and Christina A. Boros³, ¹Paediatric Rheumatology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia, ²Chemical Pathology and Molecular Genetics, SA Pathology, North Adelaide, SA 5006, Australia, ³Paediatrics, University of Adelaide/Women's and Children's Hospital, Adelaide, Australia
Background/Purpose: The prostanoids are a family of biologically active lipids derived from the 20-carbon essential fatty acids (LCPUFA) all of which are involved in the…
Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Michele Hooper¹, Deborah Wenkert², Bojena Bitman³, Virgil C. Dias⁴, Yessinia Bartley⁵, Julie Wang⁶ and Julia R. Gage⁷, ¹Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ²Inflammation TA, Amgen Inc., Thousand Oaks, CA, ³Amgen, Inc., San Francisco, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Assent Consulting, Solana Beach, CA, ⁶Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, ⁷Gage Medical Writing, LLC, Oak Park, CA
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…
Abstract Number: 321 • 2012 ACR/ARHP Annual Meeting
Glycosylation of Vitamin D Binding Protein Reduced in Juvenile Idiopathic Arthritis Patients At Risk of Disease Extension
David S. Gibson¹, Sorcha Finnegan², Gwen Manning³, Mark Duncan⁴, Stephen R. Pennington⁵, Terry L. Moore⁶ and Madeleine Rooney⁷, ¹Centre for Infection and immunity, Arthritis Research Group, Queens University Belfast, Belfast, United Kingdom, ²Centre for Infection and Immunity, Queen's University, Belfast, Belfast, United Kingdom, ³Proteome Research Centre, University College Dublin, Dublin, Ireland, ⁴Division of Endocrinology, University of Colorado, Denver, ⁵UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland, ⁶Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO, ⁷Medicine, Queens University Belfast, Belfast, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises a poorly understood group of chronic, childhood onset, autoimmune diseases with variable clinical outcomes.We investigated whether profiling of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].